Syn-Med-Chemist-"Quintessential Synthetic Chemistry"---A Synthetic Chemist's Perception......
Monday, April 18, 2016
Rituximab shows second-line promise in autoimmune limbic encephalitis
Rituximab shows second-line promise in autoimmune limbic encephalitis: Rituximab is an effective and well-tolerated second-line treatment for patients with autoimmune limbic encephalitis, suggests research.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment